Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men

Bone

Volumn 40, Issue 4, 2007, Pages 913-918

  Burnett Bowie, Sherri Ann M ^a   Mendoza, Natalia ^a   Leder, Benjamin Z ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

1,25 Dihydroxyvitamin D; Fibroblast growth factor 23; Homeostasis; Hypogonadism; Phosphate

Indexed keywords

CALCITRIOL; ESTROGEN; FIBROBLAST GROWTH FACTOR 23; GONADORELIN DERIVATIVE; GOSERELIN; PHOSPHATE; SEX HORMONE; TESTOSTERONE;

ADULT; ARTICLE; BLOOD SAMPLING; DRUG EFFECT; ESTROGEN DEFICIENCY; HUMAN; HUMAN EXPERIMENT; HYPOGONADISM; IN VIVO STUDY; KIDNEY TUBULE ABSORPTION; MALE; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; TESTOSTERONE BLOOD LEVEL; URINALYSIS;

ADULT; CALCITRIOL; CALCIUM; COLLAGEN TYPE I; FIBROBLAST GROWTH FACTORS; GOSERELIN; HUMANS; HYPOGONADISM; MALE; MULTIVARIATE ANALYSIS; PARATHYROID HORMONE; PEPTIDES; PHOSPHATES; TESTOSTERONE;

EID: 33947134977     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.10.016     Document Type: Article

References (52)

1. ADHR-consortium autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat. Genet. 26 (2000) 345-348
2. Antoniucci D.M., Yamashita T., and Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 91 (2006) 3144-3149
3. Bai X., Miao D., Li J., Goltzman D., and Karaplis A.C. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145 (2004) 5269-5279
4. Baum M., Schiavi S., Dwarakanath V., and Quigley R. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 68 (2005) 1148-1153
5. Berndt T., Craig T.A., and Bowe A.E. Secreted frizzled related protein-4 is a potent tumor derived phosphaturic agent. J. Clin. Invest. 112 (2003) 785-794
6. Bijvoet O.L. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate. Clin. Sci. 37 (1969) 23-36
7. Broulik P.D., Rosenkrancova J., Ruzicka P., and Sedlacek R. Effect of alendronate administration on bone mineral density and bone strength in castrated rats. Horm. Metab. Res. 37 (2005) 414-418
8. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., and Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21 (2006) 1187-1196
9. Falch J.A., and Gautvik K.M. A longitudinal study of pre- and postmenopausal changes in calcium metabolism. Bone 9 (1988) 15-19
10. Ferrari S.L., Bonjour J.P., and Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 90 (2005) 1519-1524
11. Gallagher J.C., Riggs B.L., and DeLuca H.F. Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 51 (1980) 1359-1364
12. Goldray D., Weisman Y., Jaccard N., Merdler C., Chen J., and Matzkin H. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (d-Trp6-GnRH). J. Clin. Endocrinol. Metab. 76 (1993) 288-290
13. Gupta A., Winer K., Econs M.J., Marx S.J., and Collins M.T. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 89 (2004) 4489-4492
14. Imanishi Y., Kawata T., Kobayashi K., Ishimura E., Miki T., Arnold A., et al. Elevated expression of FGF23 in bone in primary hyperparathyroidism in vivo. J. Bone Miner. Res. 19 (2004) S133 [Abstr.]
15. Jan de Beur S.M., Finnegan R.B., and Vassiliadis J. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res. 17 (2002) 1102-1110
16. Jonsson K.B., Zahradnik R., Larsson T., White K.E., Sugimoto T., Imanishi Y., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 348 (2003) 1656-1663
17. Kobayashi K., Imanishi Y., Miyauchi A., Onoda N., Kawata T., Tahara H., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 154 (2006) 93-99
18. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145 (2004) 3087-3094
19. Larsson T., Nisbeth U., Ljunggren O., Juppner H., and Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64 (2003) 2272-2279
20. Leder B.Z., LeBlanc K.M., Schoenfeld D.A., Eastell R., and Finkelstein J.S. Differential effects of androgens and estrogens on bone turnover in normal men. J. Clin. Endocrinol. Metab. 88 (2003) 204-210
21. Lindsay R., Coutts J.R., and Hart D.M. The effect of endogenous oestrogen on plasma and urinary calcium and phosphate in oophorectomized women. Clin. Endocrinol. (Oxf.) 6 (1977) 87-93
22. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17 (2006) 1305-1315
23. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., and Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J. Urol. 161 (1999) 1219-1222
24. Masse P.G., Dosy J., Jougleux J.L., Caissie M., and Howell D.S. Bone mineral density and metabolism at an early stage of menopause when estrogen and calcium supplement are not used and without the interference of major confounding variables. J. Am. Coll. Nutr. 24 (2005) 354-360
25. Morris H.A., Porter S.J., Durbridge T.C., Moore R.J., Need A.G., and Nordin B.E. Effects of oophorectomy on biochemical and bone variables in the rat. Bone Miner. 18 (1992) 133-142
26. Nagano N., Miyata S., Abe M., Kobayashi N., Wakita S., Yamashita T., et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 69(3) (2006) 531-537
27. O'Brien S.P., Bowe A.E., Byrne A., Weber W., Pragnell M., Kumar R., et al. FGF23 and FRP4 internalize sodium-phosphate co-transporter (NaPi2a) in opposum kidney proximal tubule cells. J. Bone Miner. Res. 18 (2003) S330
28. Pande S., Ritter C.S., Schiavi S.C., and Brown A.J. FGF-23 in chronic kidney disease and post renal transplantation. J. Bone Miner. Res. 18 (2003) S293 [Abstr.]
29. Perwad F., Azam N., Zhang M.Y., Yamashita T., Tenenhouse H.S., and Portale A.A. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146 (2005) 5358-5364
30. Ralston S.H., Fogelman I., Leggate J., Hart D.M., Farrish E., Fletcher C.D., et al. Effect of subdermal oestrogen and oestrogen/testosterone implants on calcium and phosphorus homeostasis after oophorectomy. Maturitas 6 (1984) 341-344
31. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112 (2003) 683-692
32. Rowe P.S., de Zoysa P.A., Dong R., Wang H.R., White K.E., Econs M.J., et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67 (2000) 54-68
33. Rowe P.S., Kumagai Y., Gutierrez G., Garrett I.R., Blacher R., Rosen D., et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34 (2004) 303-319
34. Saito H., Maeda A., Ohtomo S., Hirata M., Kusano K., Kato S., et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280 (2005) 2543-2549
35. Selby P.L., Peacock M., Barkworth S.A., Brown W.B., and Taylor G.A. Early effects of ethinyloestradiol and norethisterone treatment in post-menopausal women on bone resorption and calcium regulating hormones. Clin. Sci. (Lond.) 69 (1985) 265-271
36. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19 (2004) 429-435
37. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113 (2004) 561-568
38. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
39. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. [see comment]. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6500-6505
40. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem. Biophys. Res. Commun. 314 (2004) 409-414
41. Singh R.J., and Kumar R. Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin. Proc. 78 (2003) 826-829
42. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23 (2004) 421-432
43. Stepan J.J., Lachman M., Zverina J., Pacovsky V., and Baylink D.J. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocrinol. Metab. 69 (1989) 523-527
44. Tan M.O., Yilmaz C., Uygur M.C., Duyur B., and Erol D. Effects of combined androgen blockade on bone metabolism and density in men with locally advanced prostate cancer. Int. Urol. Nephrol. 34 (2002) 75-79
45. Tebben P., Singh R.J., Bungum A.O., and Kumar R. Elevated serum fibroblast growth factor 23 in patients with small cell lung cancer with normal serum phosphorus. J. Bone Miner. Res. 19 (2004) S121 [Abstr.]
46. Tebben P.J., Singh R.J., Clarke B.L., and Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin. Proc. 79 (2004) 1508-1513
47. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Yasutake J., et al. Identification of essential molecule responsible for tissue specific FGF23. J. Bone Miner. Res. 20 (2005) S345 [abstract]
48. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Oxf.) 54 (2001) 739-750
49. White K.E., Jonsson K.B., Carn G., Hampson G., Spector T.D., Mannstadt M., et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J. Clin. Endocrinol. Metab. 86 (2001) 497-500
50. Yamashita H., Yamashita T., Miyamoto M., Shigematsu T., Kazama J.J., Shimada T., et al. Fibroblast growth factor (FGF)-23 in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 151 (2004) 55-60
51. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87 (2002) 4957-4960
52. Yu X., Ibrahimi O.A., Goetz R., Zhang F., Davis S.I., Garringer H.J., et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146 (2005) 4647-4656